Open AccessProlactin and TSH secretion in functional tests in patients with primary hypothyroidism and hyperprolactinemia
Author(s) -
Т. О. Чернова,
Г С Колесникова,
S. V. Mudretsova,
S. Yu. Serpukhovitin,
Н. П. Гончаров,
G. A. Goncharov
Publication year - 1994
Publication title -
problemy èndokrinologii
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.124
H-Index - 5
eISSN - 2308-1430
pISSN - 0375-9660
DOI - 10.14341/probl12159
Subject(s) - metoclopramide , prolactin , medicine , endocrinology , dopaminergic , domperidone , subclinical infection , secretion , basal (medicine) , trh stimulation test , prolactin cell , thyrotropin releasing hormone , hormone , dopamine , insulin , vomiting
It was previously proposed that hyperprolactinemia in primary hypothyroidism is caused by enhanced release of hypothalamic TRH leading to elevation of both TSH and prolactin levels. Since the dopaminergic system is involved in regulation of prolactin and TSH secretion, we attempted to evaluate the origin of hyperprolactinemia in patients with primary hypothyroidism using tests with metoclopramide, a dopaminergic blocker (10 mg, i.v) and TRH. Two groups of patients were examined: 20 women with primary hypothyroidism and normal prolactin levels (group A) and 10 women with primary hypothyroidism and hyperprolactinemia (mean basal prolactin level 1514.8 + 300.8 mIU/ml). Prolactin reaction in metoclopramide test in group A was markedly increased vs. control group (1131 and 776%, respectively). In group В prolactin reaction in metoclopramide test was blurred (299%), similarly as in patients with microprolactinomas. We came to a conclusion that hyperprolactinemia in patients with primary hypothyroidism is unlikely to be caused by excessive TRH release, but possibly by the presence of subclinical microadenoma which manifests by the hypothyroid state or, possibly, by disturbed dopaminergic regulation of prolactin and TSH secretion in patients with primary hypothyroidism.